- Home
- SKYH vs CANF Comparison
SKYH vs CANF Comparison
Compare SKYH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYH
- CANF
- Stock Information
- Founded
- SKYH 2017
- CANF 1994
- Country
- SKYH United States
- CANF Israel
- Employees
- SKYH N/A
- CANF N/A
- Industry
- SKYH Military/Government/Technical
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SKYH Industrials
- CANF Health Care
- Exchange
- SKYH Nasdaq
- CANF Nasdaq
- Market Cap
- SKYH N/A
- CANF 7.9M
- IPO Year
- SKYH N/A
- CANF N/A
- Fundamental
- Price
- SKYH $10.78
- CANF $1.09
- Analyst Decision
- SKYH Strong Buy
- CANF Strong Buy
- Analyst Count
- SKYH 2
- CANF 2
- Target Price
- SKYH $15.25
- CANF $14.00
- AVG Volume (30 Days)
- SKYH 144.1K
- CANF 422.0K
- Earning Date
- SKYH 05-13-2025
- CANF 05-13-2025
- Dividend Yield
- SKYH N/A
- CANF N/A
- EPS Growth
- SKYH N/A
- CANF N/A
- EPS
- SKYH N/A
- CANF N/A
- Revenue
- SKYH $14,761,000.00
- CANF $674,000.00
- Revenue This Year
- SKYH $122.85
- CANF $461.72
- Revenue Next Year
- SKYH $61.16
- CANF N/A
- P/E Ratio
- SKYH N/A
- CANF N/A
- Revenue Growth
- SKYH 94.86
- CANF N/A
- 52 Week Low
- SKYH $8.26
- CANF $1.22
- 52 Week High
- SKYH $14.52
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SKYH 44.09
- CANF 34.28
- Support Level
- SKYH $10.76
- CANF $1.13
- Resistance Level
- SKYH $11.38
- CANF $1.19
- Average True Range (ATR)
- SKYH 0.66
- CANF 0.11
- MACD
- SKYH -0.08
- CANF -0.02
- Stochastic Oscillator
- SKYH 20.27
- CANF 1.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).